NCT07217184 2025-10-15Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMMGlaxoSmithKlinePhase 1/2 Active not recruiting30 enrolled
NCT03989414 2024-11-29A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)CelgenePhase 1/2 Active not recruiting424 enrolled